TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37968019
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (optimal medical therapy)
Study: 37968125
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP target of 110 mmHg to <130 mmHg)
Study: 37968125
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP target of 130 mmHg to <150 mmHg)
Study: 37968455
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers treatment
Study: 37968668
Drug: MenSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenSC therapy (bilateral intraovarian injection of menstrual blood-derived mesenchymal stromal cells)
Study: 37968668
Drug: MenSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenSC therapy
Study: 37968696
Drug: Post-biopsy anti-HER2
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-biopsy anti-HER2 treatment
Study: 37968696
Drug: Prior anti-HER2
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prior anti-HER2 treatment
Study: 37968718
Drug: Low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interleukin-2 immunotherapy
Study: 37968741
Drug: Two-dose AZI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose AZI (biannual azithromycin-MDA)
Study: 37968741
Drug: Four-dose AZI
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose AZI (quarterly azithromycin-MDA)
Study: 37969395
Drug: apatinib (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib (375 mg, orally, once daily)
Study: 37969395
Drug: apatinib (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib (375 mg, orally, once daily) plus etoposide (50 mg, orally on days 1-14 of each 21-day cycle)
Study: 37969640
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor blocker (atrasentan)
Study: 37969640
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer patients (before chemotherapy)
Study: 37969936
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (600 IU daily for 14-16 weeks)
Study: 37969936
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 capsule daily for 14-16 weeks)
Study: 37970718
Drug: Gruticibart (anti-FXI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gruticibart (anti-FXI mAb) 2 mg/kg administered through the venous catheter within 24 hours of placement
Study: 37971194
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once daily followed by venetoclax ramp-up to 400 mg daily for 22 additional 4-week cycles
Study: 37971723
Drug: Brolucizumab, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab, 6 mg, intravitreal injection every 4 weeks
Study: 37971723
Drug: Aflibercept, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept, 2 mg, intravitreal injection every 4 weeks
Study: 37971722
Drug: Nivolumab (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (480 mg intravenously) administered every 28 days for 4 doses
Study: 37971800
Drug: SparkRx (self-guided,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SparkRx (self-guided, mobile app-based behavioral activation therapy)
Study: 37971811
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure + Sertraline (PE + sertraline)
Study: 37972659
Drug: FGFR inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGFR inhibitors (FGFRi) therapy
Study: 37972659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MEK inhibition with FGFRi
Study: 37972659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FGFRi and MEK inhibition in an in vivo animal model
Study: 37972895
Drug: Whole-food omnivorous
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-food omnivorous meal (MEAT) containing 100 g lean ground beef, 0.45 g protein/kg body mass
Study: 37972929
Drug: Ankle block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankle block (30 ml of ropivacaine 0.5%)
Study: 37972929
Drug: Sciatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sciatic nerve block at the popliteal crease (30 ml of ropivacaine 0.5% + saphenous nerve block)
Study: 37973472
Drug: Electroacupuncture (EA1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA1) - Local EA with two abdominal acupoints, administered daily for 4 days.
Study: 37973472
Drug: Electroacupuncture (EA2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA2) - Local plus distal EA with twelve peripheral acupoints, administered daily for 4 days.
Study: 37973472
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - Conventional standard-of-care therapy for AP, no EA treatment.
Study: 37973545
Drug: Peanut, sesame
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut, sesame and tree nut allergy assessment through skin testing, specific IgE measurements and oral food challenges.
Study: 37973713
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of drug resistance mutations
Study: 37973784
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (mAbs) or antiviral drugs for COVID-19
Study: 37973784
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug treatment strategies (control group)
Study: 37973795
Drug: Carborie (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carborie (400 ml)
Study: 37973795
Drug: Plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain water (400 ml)
Study: 37973856
Drug: Intracoronary glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary glycoprotein IIb/IIIa inhibitors
Study: 37974056
Drug: Limosilactobacillus reuteri
Normalized name: Limosilactobacillus reuteri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limosilactobacillus reuteri ATCC PTA 4659 at high dose (1 × 10^11 CFU/day)
Study: 37974056
Drug: Limosilactobacillus reuteri
Normalized name: Limosilactobacillus reuteri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limosilactobacillus reuteri ATCC PTA 4659 at low dose (1 × 10^9 CFU/day)
Study: 37974084
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of norepinephrine
Study: 37974160
Drug: Ketamine infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusions (up to eight infusions, twice-weekly over four weeks)
Study: 37974160
Drug: Midazolam (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (active comparator, twice-weekly over four weeks)
Study: 37974184
Drug: Intravenous idursulfase
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous idursulfase
Study: 37974280
Drug: Cerebral oximetry
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral oximetry monitoring plus treatment guideline
Study: 37975059
Drug: Intravenous branched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous branched chain amino acids (IV-BCAA) - 500 mL/day for 3 days + Lactulose; n = 39
Study: 37975371
Drug: Adjuvant Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Tislelizumab plus chemotherapy (XELOX regimen: Xeloda plus Oxaliplatin)
Study: 37975371
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone (XELOX regimen)
Study: 37975501
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block with patient-controlled intravenous analgesia (ICNB-PCIA)
Study: 37976067
Drug: DAPT (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (Aspirin 100 mg/d + Clopidogrel 75 mg/d)
Study: 37976073
Drug: 2 h-double
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 h-double dose of TDF/FTC (two pills)
Study: 37976073
Drug: 7 days-single
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days-single dose of TDF/FTC (daily pill)
Study: 37976073
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 2 h-double dose and 7 days-single dose
Study: 37976073
Drug: 2 h-double
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 h-double dose of TDF/FTC
Study: 37976072
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg twice daily (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Study: 37976257
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MBSR and CCT
Study: 37976391
Drug: Terlipressin (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (median daily dose 4.3 mg/day, mean duration 6.4 days)
Study: 37976391
Drug: Pretreatment biomarkers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment biomarkers (CysC > 2.2 mg/l)
Study: 37976391
Drug: Pretreatment biomarkers
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment biomarkers (N-terminal proBNP > 350 pg/mL)
Study: 37976444
Drug: Tiragolumab 600
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab 600 mg plus atezolizumab 1,200 mg and carboplatin/etoposide (CE)
Study: 37976444
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo plus atezolizumab 1,200 mg and CE)
Study: 37976633
Drug: pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 200 mg Q3W intravenously for up to 35 cycles
Study: 37976633
Drug: chemotherapy (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (treatment of physician's choice per local/country guidelines)
Study: 37977105
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HR+/HER2- mBC in women aged <40
Study: 37977105
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HR+/HER2- mBC in women aged 40-69
Study: 37977105
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for TN mBC in women aged <40
Study: 37977105
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for TN mBC in women aged 40-69
Study: 37977105
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HER2+ mBC in women aged <40
Study: 37977105
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment for HER2+ mBC in women aged 40-69
Study: 37977178
Drug: Self-reported adherence
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported adherence to antiretroviral therapy (ARV)
Study: 37977257
Drug: Choice architecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice architecture intervention (banner of daily school meal menu, waterproof tablecloths, posters on healthy eating habits, playful names displays, new containers for fruits, colored footprints) for one month
Study: 37977713
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (1.3 × 10^14 vg/kg)
Study: 37977713
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (1.3 × 10^15 vg/kg)
Study: 37977865
Drug: Tight blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight blood pressure control with norepinephrine infusion targeting intraoperative MAP ≥85 mm Hg
Study: 37977903
Drug: Serplulimab plus
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab plus chemotherapy (etoposide and carboplatin) for four to six cycles, followed by maintenance therapy with serplulimab for up to 2 years.
Study: 37977942
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine (200 μg total toxoid)
Study: 37977942
Drug: C difficile
Normalized name: Clostridioides difficile
Approvals — FDA: no, EMA: no, PMDA: no
Description: C difficile vaccine
Study: 37978159
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (25 mg/kg loading dose then 10 mg/kg/6 h for 5 days)
Study: 37978159
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (dose level 1)
Study: 37978159
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen (dose level 2)
Study: 37978284
Drug: Tovorafenib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tovorafenib (420 mg)
Study: 37978309
Drug: Moderate-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg plus ezetimibe)
Study: 37978309
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin (rosuvastatin 20 mg) monotherapy
Study: 37978378
Drug: Cellular bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular bone allograft (CBA) used as primary graft material (≥ 50% by volume) with augmentation up to 50%
Study: 37978474
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no i-PRF injection)
Study: 37978528
Drug: Strategies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies to develop stakeholder interrelationships (35% in Preparation phase, 31% in Implementation phase)
Study: 37978528
Drug: Strategies in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies in the use iterative and evaluative approaches cluster (24% in Preparation phase, 18% in Implementation phase)
Study: 37978951
Drug: Everolimus, 5
Normalized name: Everolimus, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus, 5 mg/m² orally
Study: 37979133
Drug: PVAB regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVAB regimen (prednisone 40 mg/m2 days 1-5, vinblastine 6 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, bendamustine 120 mg/m2 day 1) every 21 days for 6 cycles
Study: 37979218
Drug: d-cycloserine augmentation
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-cycloserine augmentation with group exposure therapy
Study: 37979594
Drug: High-dose short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose short-course oral primaquine (7 mg/kg over 7 days)
Study: 37979594
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (single dose oral primaquine of 0.25 mg/kg)
Study: 37979594
Drug: High-dose short-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose short-course oral primaquine
Study: 37980367
Drug: Enzalutamide plus
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide plus CC-115 (5 mg twice a day)
Study: 37980494
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual care (EUC) (primary care treatment as usual, printed overdose prevention educational materials, educational video on cancer screening)
Study: 37980511
Drug: Bladder-sparing therapies
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder-sparing therapies (BST)
Study: 37980875
Drug: Group iterative
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group iterative multiple model estimation (GIMME) applied to examine the relationships between various emotions and suicidal ideation (SI) among individuals with borderline personality disorder who underwent Dialectical Behavior Therapy.
Study: 37980921
Drug: Systemic and
Normalized name: Estradiol and Levonorgestrel Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic and local therapy group (n=53)
Study: 37980921
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy only group (n=51)
Study: 37980924
Drug: Apixaban (weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (weight-adjusted twice-daily)
Study: 37981049
Drug: SY-009 (1.0-4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-009 (1.0-4.0 mg)
Study: 37981596
Drug: Deucravacitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib (both doses)
Study: 37981665
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin gel applied weekly for four weeks after SRP
Study: 37981892
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) and 'on-demand' plerixafor
Study: 37982276
Drug: High-sensitivity C-reactive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity C-reactive protein quartile 4 (≥4.0 mg/L)
Study: 37982381
Drug: Single LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single LMWH injection
Study: 37982575
Drug: Oral ERα
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ERα degraders
Study: 37982585
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg twice a day (BID) with rifampicin 600 mg OD (PK3)
Study: 37982585
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg once daily (OD) with rifampicin 600 mg (PK2)
Study: 37982585
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg BID with rifampicin 1200 mg OD (PK4)
Study: 37982585
Drug: Atazanavir/ritonavir 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir 300/100 mg OD (baseline, PK1)
Study: 37982827
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/day for 21 days per cycle, administered for two cycles during IMRT) + Cetuximab + Intensity-modulated radiotherapy (IMRT)
Study: 37982982
Drug: Educational brochure
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational brochure on deprescribing mailed to patients, clinician notification about brochure mailings, and monthly educational tip sheets for primary care clinicians.
Study: 37983228
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acetaminophen and fentanyl
Study: 37983375
Drug: GP-2250 (misetionamide)
Normalized name: GPS
DrugBank: Galinpepimut-S (DB17271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP-2250 (misetionamide) administered daily for 28 days at doses of 500 mg/kg, 1000 mg/kg, and 250 mg/kg
Study: 37983375
Drug: Vehicle (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (10 ml/kg) administered daily for 28 days
Study: 37983769
Drug: 3-in-1 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 single capsule with bismuth, metronidazole, and tetracycline
Study: 37983769
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy with bismuth
Study: 37983769
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with levofloxacin
Study: 37983769
Drug: 3-in-1 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 single capsule
Study: 37983769
Drug: Triple schedules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple schedules, sequential, or concomitant regimen with metronidazole
Study: 37983823
Drug: Carotid FTc
Normalized name: (-)-FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid FTc combined with perioperative fluid therapy (8 ml/kg of balanced crystalloids)
Study: 37983823
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative fluid therapy
Study: 37984383
Drug: Vosoritide (30·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vosoritide (30·0 μg/kg for infants aged 0-23 months; 15·0 μg/kg for children aged 24-59 months)
Study: 37984453
Drug: RPT193 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPT193 (oral CCR4 antagonist), once-daily treatment
Study: 37984741
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g prune/d
Study: 37984741
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g prune/d